Bicycle Therapeutics Q4 Revenue $47.96M, Exceeds Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 14 hours ago
0mins
Should l Buy BCYC?
Reports Q4 revenue $47.96M, consensus $7.08M. The increases in collaboration revenue of $44.3M and $37.3M for the three months and year ended December 31, 2025, respectively, were primarily due to the recognition of all remaining revenue under Bicycle Therapeutics' collaboration with Novartis Pharma AG upon a notice of termination of the collaboration agreement, as well as the recognition of revenue under Bicycle Therapeutics' collaboration with Bayer Consumer Care AG upon a notice of termination of one of the target programs under the collaboration agreement. "We have successfully completed the dose selection portion of the Duravelo-2 trial and received regulatory alignment that the 6mg dose and schedule is optimal for zelenectide in mUC based on strong anti-tumor activity and its differentiated safety profile. We look forward to sharing these data at an upcoming scientific conference. Based on the regulatory feedback we have received, the existing Duravelo-2 trial design is no longer considered acceptable as an approval path for zelenectide in mUC. Preliminary discussions with regulatory agencies have outlined several potential paths for zelenectide's approval in mUC. While we believe the strength of these data and the clear medical need justify continued development of zelenectide, we have reached the difficult decision to deprioritize this program for internal development at this time. We have initiated a process to convert our ongoing Duravelo-2 trial to a randomized Phase 2 study. Once we have these randomized Phase 2 data in hand, we will determine the most appropriate path for zelenectide," said Bicycle Therapeutics CEO Kevin Lee. "We believe these data provide further validation of the ability of our Bicycle technology to deliver oncology therapeutics with a potentially improved benefit/risk profile compared to existing modalities. In view of this, we have decided to conduct a strategic reprioritization, which includes a proposed workforce reduction, to best position the company to focus our resources on our promising pipeline of next-generation therapeutics."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BCYC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BCYC
Wall Street analysts forecast BCYC stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 5.050
Low
24.00
Averages
24.00
High
24.00
Current: 5.050
Low
24.00
Averages
24.00
High
24.00
About BCYC
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bicycle Therapeutics Q4 Earnings Exceed Expectations
- Strong Earnings Report: Bicycle Therapeutics reported a Q4 GAAP EPS of -$0.29, beating expectations by $0.66, indicating a significant improvement in financial performance and reflecting the potential value of its business model.
- Revenue Surge: The company achieved Q4 revenue of $47.96 million, a staggering 1192.7% year-over-year increase, surpassing market expectations by $40.88 million, demonstrating robust demand and rapid growth for its products or services.
- Healthy Cash Position: As of December 31, 2025, Bicycle Therapeutics holds $628 million in cash and cash equivalents, with an expected cash runway extending into 2030, enhancing the company's flexibility for future investments and operations.
- Strategic Restructuring Plan: The company plans to reduce its workforce by approximately 30% to optimize resource allocation and improve operational efficiency, a move that not only helps lower costs but may also enhance the company's long-term sustainability in the competitive biopharmaceutical industry.
See More
Bicycle Therapeutics Restructures and Lays Off 30% of Workforce
- Strategic Restructuring: Bicycle Therapeutics announced a reprioritization of certain programs and a layoff of approximately 30% of its workforce to focus on its most promising candidates, resulting in an expected 50% reduction in annual operating expenses.
- Pipeline Focus: The company will concentrate its research efforts on BT5528 (also known as nuzefatide pevedotin), a potentially first-in-class EphA2-targeting drug conjugate currently in phase I/II clinical trials, aimed at treating metastatic pancreatic ductal adenocarcinoma, indicating strong market potential.
- Clinical Trial Progress: BT5528 is being tested as a monotherapy and in combination with an immune checkpoint inhibitor in phase I/II trials, while also undergoing a phase II trial as a monotherapy for metastatic pancreatic ductal adenocarcinoma, showcasing its potential in cancer treatment.
- Asset De-prioritization: Bicycle Therapeutics will deprioritize its most advanced drug conjugate, zelenectide pevedotin, which targets Nectin-4 expressing tumors and was previously in a phase II trial for metastatic urothelial cancer, reflecting the company's strategic resource allocation adjustments.
See More
Bicycle Therapeutics Appoints New CFO
- Executive Changes: Bicycle Therapeutics has appointed Travis Thompson as the new Chief Financial Officer, who previously served as the company's Senior Vice President and Chief Accounting Officer, continuing to oversee finance and accounting functions while taking on investor relations, which is expected to enhance communication efficiency with investors.
- Interim Transition Plan: Former CFO Alethia Young will remain in an interim capacity for the next three months before transitioning to a company advisor role, a move designed to ensure continuity and stability in financial management while mitigating potential risks associated with executive turnover.
- Medical and Technology Leadership Adjustments: The company has also promoted Michael Method to Chief Medical Officer, while Michael Skynner, Ph.D., is transitioning to Chief Scientific Officer, which will strengthen the company's leadership in research and development and drive innovation.
- Strategic Restructuring: These executive changes reflect Bicycle Therapeutics' strategic emphasis on enhancing financial, medical, and technological management, aiming to support the company's long-term growth objectives through an optimized leadership team.
See More
Bicycle Therapeutics Signs 15-Year Contract with UK NDA for 400 Tonnes of Reprocessed Uranium
- Strategic Partnership: Bicycle Therapeutics has signed a 15-year contract with the UK Nuclear Decommissioning Authority to access up to 400 tonnes of reprocessed uranium, which is expected to provide a sustainable supply of 212Pb for its potential lifesaving therapies, significantly enhancing its competitive edge in the radiopharmaceutical sector.
- Technological Innovation: Through collaboration with the UK National Nuclear Laboratory, Bicycle plans to extract 228Th from the reprocessed uranium and further process it into 224Ra, developing a bespoke 212Pb generator that will drive the development of its radioconjugate portfolio.
- Market Potential: Bicycle's radioconjugates (BRCs) will utilize 212Pb as a potent therapeutic payload against cancer, expected to offer new treatment options for cancer patients worldwide, presenting significant market opportunities and societal impact.
- R&D Progress: Bicycle aims to present initial EphA2 human imaging data in the first half of 2026 and initiate its own clinical study, marking ongoing advancements in radiopharmaceutical development and establishing its position as a potential leader in the field.
See More
Bicycle Therapeutics Signs 15-Year Contract with UK NDA for 400 Tonnes of Reprocessed Uranium
- Long-Term Partnership: Bicycle Therapeutics has signed a 15-year contract with the UK Nuclear Decommissioning Authority, securing access to up to 400 tonnes of reprocessed uranium, which will provide a sustainable raw material supply for its potential lifesaving therapies, significantly enhancing the company's R&D capabilities.
- Radioisotope Development: Through collaboration with the UK National Nuclear Laboratory, Bicycle plans to extract 228Th from the reprocessed uranium, further processing it into a 212Pb generator, with the potential to deliver tens of thousands of doses of 212Pb annually, advancing targeted cancer therapies.
- Customized Generator: Bicycle has partnered with SpectronRx to develop a bespoke 212Pb generator, with initial quantities of 212Pb successfully produced, which will provide strong support for the company's competitive position in the radiopharmaceutical market.
- Strategic Investment Outlook: The CEO of Bicycle stated that these collaborations demonstrate the company's potential in radiopharmaceutical R&D, with expectations to advance its BRC product line and present initial human imaging data in the first half of 2026, further solidifying its market position.
See More
Bicycle Therapeutics Under Investigation, ADR Price Drops 7.88%
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Bicycle Therapeutics plc has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to stock price volatility.
- Analyst Downgrade: RBC Capital Markets analyst Leonid Timashev downgraded Bicycle from Outperform to Sector Perform, citing delays in dose selection for its drug in phase 2/3 development for metastatic urothelial cancer, pushing timelines to Q1 2026, which threatens its competitive position in a growing market.
- Increased Competition Impact: Timashev noted that any further delays from Bicycle will benefit competing products from Pfizer, potentially leading to a loss of market share and negatively impacting future revenue expectations.
- Stock Price Reaction: Following the downgrade, Bicycle's American Depositary Receipt (ADR) price fell by $0.69, or 7.88%, closing at $8.07, reflecting market concerns regarding the company's outlook.
See More
Bicycle Therapeutics Q4 Earnings Exceed Expectations
- Strong Earnings Report: Bicycle Therapeutics reported a Q4 GAAP EPS of -$0.29, beating expectations by $0.66, indicating a significant improvement in financial performance and reflecting the potential value of its business model.
- Revenue Surge: The company achieved Q4 revenue of $47.96 million, a staggering 1192.7% year-over-year increase, surpassing market expectations by $40.88 million, demonstrating robust demand and rapid growth for its products or services.
- Healthy Cash Position: As of December 31, 2025, Bicycle Therapeutics holds $628 million in cash and cash equivalents, with an expected cash runway extending into 2030, enhancing the company's flexibility for future investments and operations.
- Strategic Restructuring Plan: The company plans to reduce its workforce by approximately 30% to optimize resource allocation and improve operational efficiency, a move that not only helps lower costs but may also enhance the company's long-term sustainability in the competitive biopharmaceutical industry.
See More
Bicycle Therapeutics Restructures and Lays Off 30% of Workforce
- Strategic Restructuring: Bicycle Therapeutics announced a reprioritization of certain programs and a layoff of approximately 30% of its workforce to focus on its most promising candidates, resulting in an expected 50% reduction in annual operating expenses.
- Pipeline Focus: The company will concentrate its research efforts on BT5528 (also known as nuzefatide pevedotin), a potentially first-in-class EphA2-targeting drug conjugate currently in phase I/II clinical trials, aimed at treating metastatic pancreatic ductal adenocarcinoma, indicating strong market potential.
- Clinical Trial Progress: BT5528 is being tested as a monotherapy and in combination with an immune checkpoint inhibitor in phase I/II trials, while also undergoing a phase II trial as a monotherapy for metastatic pancreatic ductal adenocarcinoma, showcasing its potential in cancer treatment.
- Asset De-prioritization: Bicycle Therapeutics will deprioritize its most advanced drug conjugate, zelenectide pevedotin, which targets Nectin-4 expressing tumors and was previously in a phase II trial for metastatic urothelial cancer, reflecting the company's strategic resource allocation adjustments.
See More
Bicycle Therapeutics Appoints New CFO
- Executive Changes: Bicycle Therapeutics has appointed Travis Thompson as the new Chief Financial Officer, who previously served as the company's Senior Vice President and Chief Accounting Officer, continuing to oversee finance and accounting functions while taking on investor relations, which is expected to enhance communication efficiency with investors.
- Interim Transition Plan: Former CFO Alethia Young will remain in an interim capacity for the next three months before transitioning to a company advisor role, a move designed to ensure continuity and stability in financial management while mitigating potential risks associated with executive turnover.
- Medical and Technology Leadership Adjustments: The company has also promoted Michael Method to Chief Medical Officer, while Michael Skynner, Ph.D., is transitioning to Chief Scientific Officer, which will strengthen the company's leadership in research and development and drive innovation.
- Strategic Restructuring: These executive changes reflect Bicycle Therapeutics' strategic emphasis on enhancing financial, medical, and technological management, aiming to support the company's long-term growth objectives through an optimized leadership team.
See More
Bicycle Therapeutics Signs 15-Year Contract with UK NDA for 400 Tonnes of Reprocessed Uranium
- Strategic Partnership: Bicycle Therapeutics has signed a 15-year contract with the UK Nuclear Decommissioning Authority to access up to 400 tonnes of reprocessed uranium, which is expected to provide a sustainable supply of 212Pb for its potential lifesaving therapies, significantly enhancing its competitive edge in the radiopharmaceutical sector.
- Technological Innovation: Through collaboration with the UK National Nuclear Laboratory, Bicycle plans to extract 228Th from the reprocessed uranium and further process it into 224Ra, developing a bespoke 212Pb generator that will drive the development of its radioconjugate portfolio.
- Market Potential: Bicycle's radioconjugates (BRCs) will utilize 212Pb as a potent therapeutic payload against cancer, expected to offer new treatment options for cancer patients worldwide, presenting significant market opportunities and societal impact.
- R&D Progress: Bicycle aims to present initial EphA2 human imaging data in the first half of 2026 and initiate its own clinical study, marking ongoing advancements in radiopharmaceutical development and establishing its position as a potential leader in the field.
See More
Bicycle Therapeutics Signs 15-Year Contract with UK NDA for 400 Tonnes of Reprocessed Uranium
- Long-Term Partnership: Bicycle Therapeutics has signed a 15-year contract with the UK Nuclear Decommissioning Authority, securing access to up to 400 tonnes of reprocessed uranium, which will provide a sustainable raw material supply for its potential lifesaving therapies, significantly enhancing the company's R&D capabilities.
- Radioisotope Development: Through collaboration with the UK National Nuclear Laboratory, Bicycle plans to extract 228Th from the reprocessed uranium, further processing it into a 212Pb generator, with the potential to deliver tens of thousands of doses of 212Pb annually, advancing targeted cancer therapies.
- Customized Generator: Bicycle has partnered with SpectronRx to develop a bespoke 212Pb generator, with initial quantities of 212Pb successfully produced, which will provide strong support for the company's competitive position in the radiopharmaceutical market.
- Strategic Investment Outlook: The CEO of Bicycle stated that these collaborations demonstrate the company's potential in radiopharmaceutical R&D, with expectations to advance its BRC product line and present initial human imaging data in the first half of 2026, further solidifying its market position.
See More
Bicycle Therapeutics Under Investigation, ADR Price Drops 7.88%
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Bicycle Therapeutics plc has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to stock price volatility.
- Analyst Downgrade: RBC Capital Markets analyst Leonid Timashev downgraded Bicycle from Outperform to Sector Perform, citing delays in dose selection for its drug in phase 2/3 development for metastatic urothelial cancer, pushing timelines to Q1 2026, which threatens its competitive position in a growing market.
- Increased Competition Impact: Timashev noted that any further delays from Bicycle will benefit competing products from Pfizer, potentially leading to a loss of market share and negatively impacting future revenue expectations.
- Stock Price Reaction: Following the downgrade, Bicycle's American Depositary Receipt (ADR) price fell by $0.69, or 7.88%, closing at $8.07, reflecting market concerns regarding the company's outlook.
See More
